Health

FDA OKs limited use of Tysabri

NEWS IN BRIEF — Posted June 26, 2006

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

The Food and Drug Administration decided June 5 to allow Tysabri (natalizumab) to be prescribed once more, although this time with numerous restrictions. The drug had been approved in November 2004 for patients with relapsing forms of multiple sclerosis but was removed from the market in February 2005 by its manufacturer after three patients in the drug's clinical trials developed a serious brain infection -- two died as a result.

The drug, a monoclonal antibody, had been hailed as an important new treatment.

Under the new prescribing restrictions, Tysabri is to be used alone rather than in combination with other immune-system-modifying drugs and only for patients who have not responded adequately to, or cannot tolerate, other treatments for MS.

In addition, the FDA is adopting a requirement recommended by its Peripheral and Central Nervous System Drugs Advisory Committee that there be mandatory patient registration and periodic follow-up to identify as early as possible any cases of progressive multifocal leukoencephalopathy, or PML, that may occur and to try to determine the reason for the infection.

Prescribers, pharmacies and infusion centers who handle the drug also will have to register with the risk management plan, called the TOUCH Prescribing Program, developed by manufacturer Biogen Idec. Before initiating the therapy, patients must have an MRI scan to help differentiate potential future multiple sclerosis symptoms from PML.

Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/06/26/hlbf0626.htm.

Back to top


ADVERTISEMENT

ADVERTISE HERE


Featured
Read story

Confronting bias against obese patients

■ Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story


Read story

Goodbye

■ American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story


Read story

Policing medical practice employees after work

■ Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story


Read story

Diabetes prevention: Set on a course for lifestyle change

■ The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story


Read story

Medicaid's muddled preventive care picture

■ The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story


Read story

How to get tax breaks for your medical practice

■ Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story


Read story

Advance pay ACOs: A down payment on Medicare's future

■ Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story


Read story

Physician liability: Your team, your legal risk

■ When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn